↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, December 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
48 Mendeley
Title
Clinical factors and comorbidities affecting the cost of hospital-treated COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, December 2016
DOI 10.2147/copd.s120637
Pubmed ID
Authors

Sami Deniz, Aysun Şengül, Yusuf Aydemir, Julide Celdir Emre, Mustafa Hikmet Ozhan

Abstract

We aimed to assess the effects of comorbidities on COPD costs and to investigate the relationship between comorbidities and clinical variables. All patients hospitalized with a diagnosis of COPD exacerbation between January 1, 2014, and December 31, 2014, at all state hospitals of Aydın province, a city located in the western part of Turkey, were included in this study. The costs examined in the study pertained to medications, laboratory tests, hospital stays, and other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees. A total of 3,095 patients with 5,237 exacerbations (mean age, 71.9±10.5 years; 2,434 males and 661 females) were evaluated. For 880 of the patients (28.9%), or 3,852 of the exacerbations (73.1%), at least one comorbid disease was recorded. The mean cost of each exacerbation was $808.5±1,586, including $325.1±879.9 (40.7%) for hospital stays, $223.1±1,300.9 (27.6%) for medications, $46.3±49.6 (0.9%) for laboratory expenditures, and $214±1,068 (26.5%) for other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees. The cost of each exacerbation was $1,014.9 in patients with at least one comorbidity, whereas it was $233.6 in patients without comorbidity (P<0.001). Age >65 years, female gender, hospitalization in an intensive care unit, invasive or noninvasive mechanical ventilation, and a long duration of hospitalization were all found to be significant factors in increasing total costs during the exacerbations requiring hospitalization (P<0.05 for all). Comorbidities have an important role in the total costs of acute exacerbations of COPD. Strategies for the prevention, diagnosis, and effective management of comorbidities would decrease the overall financial burden associated with acute exacerbations of COPD.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 25%
Student > Ph. D. Student 5 10%
Researcher 5 10%
Student > Bachelor 5 10%
Student > Doctoral Student 3 6%
Other 5 10%
Unknown 13 27%
Readers by discipline Count As %
Medicine and Dentistry 12 25%
Nursing and Health Professions 8 17%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Biochemistry, Genetics and Molecular Biology 2 4%
Psychology 2 4%
Other 4 8%
Unknown 15 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2016.
All research outputs
#6,648,707
of 8,729,235 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#882
of 1,139 outputs
Outputs of similar age
#206,885
of 298,628 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#76
of 86 outputs
Altmetric has tracked 8,729,235 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,139 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,628 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.